Blog

Read the latest perspectives from our team of subject matter experts and others

doctor speaking with patient

FDA Poised to Make Impact on Underrepresented Populations in Clinical Studies

Diversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing diversity in clinical trials not only makes the… Continue reading →

Read the article

Diversity & Inclusion Drug Development
FDA Poised to Make Impact on Underrepresented Populations in Clinical Studies
Diversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing diversity in clinical trials not only makes the… Continue reading →

Read the article
yes
Diversity & Inclusion Drug Development
The Opportunities and Challenges of Improving Health Equity with Expert Daniel Perez
The pursuit of health equity has many obstacles. Achieving a state where everyone has fair and equitable access to healthcare is a massive endeavor with many stakeholders. It requires addressing… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
Ethics and Equity in Clinical Trials & FDA Diversity Guidance Prep
Clinical trials serve as the bedrock for advancements in medicine, guiding the development of new treatments and therapies. However, a critical issue plaguing these trials is the lack of… Continue reading →

Read the article
no
Artificial Intelligence Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
Trials, Data, Diversity – H1’s Top 5 Diagnoses (Predictions) for Biotech and Pharma in 2024
How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life… Continue reading →

Read the article
no
Artificial Intelligence Commercialization Drug Development
Six Possible Implications of Biden’s Executive Order on AI for Life Sciences
The life sciences sector stands on the brink of a new era marked by the confluence of artificial intelligence (AI) and biomedicine. With President Biden’s recent Executive Order on AI,… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
Why Clinical Trial Success Criteria Matters: 5 Essential Questions
As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. With the rise of… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
Optimizing Clinical Data Registries: Opportunities for Diversity and Feasibility
In an October 2023 report, BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical… Continue reading →

Read the article
no
Artificial Intelligence Drug Development
4 AI predictions for the Life Sciences Sector by 2025
The application of AI in the life sciences sector has the potential to revolutionize many aspects of research, development, and patient care. By 2025, we can anticipate pretty significant shifts… Continue reading →

Read the article
no
Artificial Intelligence Commercialization Diversity & Inclusion Drug Development
7 Ways of Generating AI-produced ROI for Life Sciences
For life sciences companies, the application of AI has the potential to provide transformative value, not only in terms of direct financial return but also through operational, research, and clinical… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
The Trust Fall: Building Successful & Diverse Trials Outside the U.S.
As the U.S. ramps up for release of the latest COVID-19 vaccine booster, the Centers for Disease Control and Prevention (CDC) recommends that all Americans aged 6 months and… Continue reading →

Read the article
no
Drug Development
4 Ways CROs Can Ensure a Bright Future for Pharma
As pharmaceutical companies turn to CROs (Clinical Research Organizations) for trial design and technology, there are new opportunities emerging with healthcare data intelligence that can help ensure a bright future… Continue reading →

Read the article
no
Commercialization Drug Development
What Payer Trends Can Tell Us About Medication Adherence
One of the most important aspects of monitoring payer trends is getting an accurate picture of patient utilization. Understanding which treatments are being utilized, by whom, and for what… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
Improving Oncology Clinical Trials for Accelerated Approval
In March of 2023, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design specific… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
Why Drug Approvals and Development Hinge on Diversity
The success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development KOL Engagement
Building an Exclusive Strategy with Inclusive HCPs
As healthcare providers (HCPs) are increasingly relying on evidence-based data and clinical guidelines, life science organizations must shift their focus to enabling HCPs in the effective adoption of these medicines.… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
A Lesson in History: Assessing Trial Performance Data for Future Trial Design
Clinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. Performance data on principal investigators and clinical trial sites provides invaluable insights to… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
Four Strategies for Preparing FDA Diversity Action Plans
In the race to bring new treatments and cures to market, clinical trial operations and feasibility teams often face a formidable challenge: ensuring that patient populations are accurately represented… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
3 Ways CROs Can Expedite Clinical Trial Site Success
Clinical Research Organizations (CROs) play an important role in the success of clinical trials. They provide crucial resources, processes, and strategies to ensure that trials are conducted with the… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
Data Networks & Guiding Clinical Trials – Six Metrics for Powering Trials to Reach Vulnerable Patient Populations
For clinical operations and development clinical feasibility teams, diversity equity and inclusion and health equity leaders, as well as health economics and outcomes research (HEOR) teams, it is essential to… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
3 Common Questions Related to Clinical Trial Performance Data
Over the past decade, the cost and time impact to bring drugs to market have been increasing. With the recent trends in healthcare (more diversity and inclusion for both patients… Continue reading →

Read the article
no
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
H1 Honored with a Spot on Y Combinator’s 2023 Best Companies List and Slice of Healthcare’s Inaugural Digital Health Leaders List
H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced that it has been recognized in two prestigious annual lists: Y Combinator’s 2023 Best Companies… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
Best-Fit Sites for Clinical Trials
When evaluating the feasibility of a clinical trial, it’s essential to consider what success means. This can mean defining criteria for your patient population, principal investigator (PI) qualifications, and… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development
Three Essential Data Insights for Optimal Trial Site Feasibility, Inclusivity and Selection
When you google the term “clinical trial,” the first thing that comes up is the National Library of Medicine site all about clinical research. It’s a great foray and… Continue reading →

Read the article
no
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
New Look, Same Commitment!
I’m excited to officially unveil the new branding and website our team has been working on for several months. This new branding comes with much thought and consideration, and reflects… Continue reading →

Read the article
no
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
Timmy Awards Announces H1 as 2022 Tech for Good Finalist
The 8th Annual Timmy Awards run by Tech in Motion celebrates leaders in tech, recognizing the top workplaces for tech professionals across North America. We are thrilled to announce that H1 is… Continue reading →

Read the article
Diversity & Inclusion Drug Development
The ABCs (and Ds) of Clinical Trial Diversity
When the FDA mandated guidelines earlier this year for broader clinical trial diversity and inclusion, it brought a long-standing challenge in pharma and life sciences into the spotlight. Here, Alexandra… Continue reading →

Read the article
no
Diversity & Inclusion Drug Development KOL Engagement
A New Reflection on Pharma, Research, and Patient Care
Pharma has long existed in elevated, prestigious academic institutions: ivory towers of reputable and revered centers of excellence famous for disseminating the latest in clinical research and medical breakthroughs.… Continue reading →

Read the article
Drug Development KOL Engagement
H1 Announces Partnership with Society for Clinical Research Sites
The Society for Clinical Research Sites (SCRS) announced today that H1, a pioneer in creating connected ecosystems where data, people, research, and clinical trial intelligence come together to drive the… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
The Evolution of H1’s Core Values
I remember it clearly. Me, Ian – our co-founder and a handful of brave individuals who would become the first H1 employees, sitting around a table writing down the values… Continue reading →

Read the article
Diversity & Inclusion Drug Development
Equitable Healthcare Starts with Medical Affairs
Because they serve as the bridge between research and commercial functions of life sciences companies, medical affairs can drive equity in clinical trials by proactively engaging with a diverse set… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
H1 Recognized as One of Forbes’ Best Startup Employers 2022
H1, which provides the largest global healthcare professional data ecosystem to enable life sciences, academic medical institutions, health systems, and payers, today announced it has been included on Forbes’… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
H1 Named to NYC Digital Health 100 by NYCHBL
H1, which provides the largest global healthcare platform that connects healthcare professionals, today announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to… Continue reading →

Read the article
Diversity & Inclusion Drug Development
Making Clinical Trials More Successful
Utilizing all available data sources to optimize clinical trial design and planning, as well as adopting novel trial formats, such as decentralized trials, telehealth and mobile health applications, can get… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
H1 Wraps Up 2021 with Gratitude
2021 was a year of enormous change around the world, as we learn to live and work in new ways. For H1, it was also a year of enormous growth,… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
Co-Founder and CEO of H1 Named to Forbes 30 Under 30
H1 announced today that its CEO and Co-Founder Ariel Katz was named to the prestigious Forbes 30 under 30 list. Ariel started his first company in college, ResearchConnection, to help… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
Ziad Ismail Joins H1 During Period of High Growth
H1, which provides the largest global healthcare network that connects healthcare professionals, announced today that it has added Ziad Ismail to the management team as Chief Operating Officer. Ziad… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
H1 Raises Series C
Today we announced our Series C of $100 million led by Altimeter and participation from new investors including Goldman Sachs Asset Management and Flex Capital. It also includes the support… Continue reading →

Read the article
Drug Development
Real World Data: Sources and Effective Evaluation
Help you understand what real world data (RWD) is and how it is used. Discuss the many sources of RWD and how tracking and measuring RWD can be challenging.… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
Former Dropbox CIO Joins Board of Healthcare Data Startup H1
Board member Sylvie Veilleux (Salesforce, Dropbox), CFO Karen Moran (Alteryx, Domo) and CDO Mayur Thakur (Goldman Sachs, Google) bring decades of experience and add bench strength as H1 expands.… Continue reading →

Read the article
Diversity & Inclusion Drug Development
The Post-Pandemic Future of Clinical Trials
In a post-COVID world, we’re seeing a decade’s worth of reshaping within clinical trials solidify in less than a year. While the life sciences industry was making a slow… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development
Why Diversity Matters for Pharma
Diversity matters for pharma because inclusion, trust and equity matter for pharma. When developing therapies and medications, pharmaceutical and life sciences companies are tasked with designing products for a… Continue reading →

Read the article
Drug Development KOL Engagement
9 Ways Medical Affairs Can Use Claims and Referral Data
In a recent interview an experienced medical affairs professional reminisced about the days when key opinion leader selection was a difficult and time consuming activity, which often relied on established… Continue reading →

Read the article
Commercialization Diversity & Inclusion Drug Development KOL Engagement Provider Data Research
H1 Closes $58 Million Series B Funding
Today, H1 announced a $58 million Series B round of funding to continue working towards our mission of creating a healthier future by connecting parties in the healthcare ecosystem.… Continue reading →

Read the article
Drug Development KOL Engagement
The Future of Medical Affairs
It is not the first time we say this: healthcare is rapidly changing and is driven by several different factors, chief among them our ability to create ever-increasing amounts… Continue reading →

Read the article
Drug Development KOL Engagement
Clinical Trial Enrollment Challenges
We talk a lot about Medical Science Liaisons (MSLs) and Key Opinion Leaders (KOLs) and their roles and responsibilities. We also dedicated a blog to the emerging role of… Continue reading →

Read the article
Drug Development KOL Engagement
The Roles of KOLs in the Drug Development Process
Key opinion leaders (KOLs) play an important role throughout the entire drug development and approval process. Most companies work with KOLs during Phases IIIa and IIIb as well as during… Continue reading →

Read the article